Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 16, 2024; 12(2): 392-398
Published online Jan 16, 2024. doi: 10.12998/wjcc.v12.i2.392
Three cancers in the renal pelvis, bladder, and colon: A case report
Jing Chen, Hua-Yan Huang, Hui-Chun Zhou, Lin-Xiao Liu, Chuang-Fan Kong, Quan Zhou, Jian-Ming Fei, Yuan-Ming Zhu, Hu Liu, Ye-Chen Tang, Cheng-Zhong Zhou
Jing Chen, Hua-Yan Huang, Hui-Chun Zhou, Lin-Xiao Liu, Chuang-Fan Kong, Yuan-Ming Zhu, Cheng-Zhong Zhou, Department of General Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang Province, China
Quan Zhou, Jian-Ming Fei, Department of Pathology, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang Province, China
Hu Liu, Department of Medical Imaging, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang Province, China
Ye-Chen Tang, Department of Urology, The Second Affiliated Hospital of Jiaxing University, Jiaxing 31400, Zhejiang Province, China
Author contributions: Chen J, Huang HY, Zhou HC, Liu LX, and Zhou CZ designed the research study; Kong CF, Zhu YM, and Liu H performed the research; Zhou Q, Fei JM, and Tang YC contributed analytic tools; Chen J and Zhou CZ analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.
Informed consent statement: Written informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cheng-Zhong Zhou, MD, Doctor, Department of General Surgery, The Second Affiliated Hospital of Jiaxing University, No. 1517 Huancheng North Road, Jiaxing 314000, Zhejiang Province, China. zhouzc1171@163.com
Received: September 20, 2023
Peer-review started: September 20, 2023
First decision: November 20, 2023
Revised: December 2, 2023
Accepted: December 22, 2023
Article in press: December 22, 2023
Published online: January 16, 2024
Abstract
BACKGROUND

Multiple primary cancers are rare occurrences that can involve either metachronous or synchronous development. It is particularly rare for an individual to have more than two primary cancers. In this report, we present a case study of an elderly man who was diagnosed with three heterochronous cancers in the renal pelvis, bladder, and colon.

CASE SUMMARY

On December 30, 2014, a 51-year-old Chinese man was admitted to our hospital with complaints of intermittent painless gross hematuria for the preceding week. A computed tomography (CT) scan revealed wall thickening in the left ureter’s upper segment, while a CT urography revealed a left renal pelvis tumor. A successful laparoscopic radical resection of the left renal pelvis tumor was subsequently performed at Shanghai Zhongshan Hospital in January 2015. The pathological findings after the surgery revealed a low-grade papillary urothelial carcinoma of the renal pelvis. The final pathological tumor stage was pT1N0M0. After surgery, this patient received 6 cycles of intravenous chemotherapy with gemcitabine and carboplatin, as well as bladder infusion therapy with gemcitabine. On December 18, 2017, the patient was admitted once again to our hospital with a one-day history of painless gross hematuria. A CT scan showed the presence of a space-occupying lesion on the posterior wall of bladder. Cystoscopic examination revealed multiple tumors in the bladder and right cutaneous ureterostomy was performed under general anesthesia on December 29, 2017. The postoperative pathological findings disclosed multifocal papillary urothelial carcinoma of the bladder (maximum size 3.7 cm × 2.6 cm). The bladder cancer was considered a metastasis of the renal pelvis cancer after surgery. The pathological tumor stage was pT1N0M1. The patient refused chemotherapy after surgery. After another six years, the patient returned on February 28, 2023, complaining of periumbilical pain that had lasted six days. This time, a CT scan of the abdomen showed a tumor in the ascending colon, but a subsequent colonoscopy examination indicated a tumor in the descending colon. On March 12, 2023, a subtotal colectomy and an ileosigmoidal anastomosis were carried out under general anesthesia. Postoperative pathological findings revealed that all three tumors were adenocarcinomas. The final pathological tumor stage was pT3N0M0. The patient had an uneventful postoperative recovery and was discharged without complications.

CONCLUSION

The case of this elderly man presents a rare occurrence of metachronous primary cancers in the renal pelvis and colon. Bladder cancer is considered a metastasis of renal pelvis cancer after surgery. Optimal treatment can be implemented by evaluating the patient’s histological features, clinical history, and tumor distribution correctly.

Keywords: Metachronous primary carcinoma, Renal pelvis carcinoma, Bladder carcinoma, Colon carcinoma, Case report

Core Tip: In this report, we present a case study of an elderly man who was diagnosed with three heterochronous cancers in the renal pelvis, bladder, and colon. The case of this elderly man presents a rare occurrence of metachronous primary cancers in the renal pelvis and colon. The bladder cancer is considered to be metastasis of renal pelvis cancer after operation. Optimal treatment can be implemented by evaluating the patient’s histological features, clinical history, and tumor distribution correctly.